As European markets navigate renewed trade and geopolitical uncertainties, with major indices like the STOXX Europe 600 Index ending lower, investors are increasingly focusing on insider ownership as a potential indicator of company confidence and alignment with shareholder interests. In this environment, growth companies with substantial insider ownership can be particularly appealing, as they may suggest management's commitment to long-term success despite broader market volatility.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name |
Insider Ownership |
Earnings Growth |
|---|---|---|
| Warimpex Finanz- und Beteiligungs (WBAG:WXF) |
25.9% |
100.6% |
| S.M.A.I.O (ENXTPA:ALSMA) |
16.1% |
76.1% |
| MilDef Group (OM:MILDEF) |
13.7% |
86.4% |
| KebNi (OM:KEBNI B) |
35% |
61.2% |
| Hanza (OM:HANZA) |
24.4% |
49.2% |
| CTT Systems (OM:CTT) |
17.5% |
52% |
| Clavister Holding AB (publ.) (OM:CLAV) |
18% |
113.2% |
| Circus (XTRA:CA1) |
21.9% |
77% |
| CD Projekt (WSE:CDR) |
29.7% |
48.7% |
| Bonesupport Holding (OM:BONEX) |
10.3% |
58.0% |
We're going to check out a few of the best picks from our screener tool.
MedinCell
Simply Wall St Growth Rating:★★★★★☆
Overview:MedinCell S.A. is a clinical-stage and commercial biopharmaceutical licensing company in France that focuses on developing long-acting injectables across various therapeutic areas, with a market cap of €918.94 million.
Operations:The company's revenue segment includes conducting research and development on biodegradable polymer-based processes, generating €32.44 million.
Insider Ownership:12.5%
MedinCell, included in the MSCI World Small Cap Index, is poised for significant growth with expected annual revenue increases of 42.6%, outpacing the French market. Despite a current net loss of €16.08 million, forecasts suggest profitability within three years and earnings growth at 58.4% annually. The company's strategic U.S. expansion under Dr Grace Kim enhances its potential value creation, although its share price remains highly volatile and trades below estimated fair value by 89%.
-
Unlock comprehensive insights into our analysis of MedinCell stock in this growth report.
-
Our valuation report unveils the possibility MedinCell's shares may be trading at a premium.
Xplora Technologies
Simply Wall St Growth Rating:★★★★★☆
Overview:Xplora Technologies AS is an information technology company that develops wearable smart devices and connectivity services for kids and families across several countries, with a market cap of NOK2.41 billion.
Operations:Xplora Technologies generates revenue by developing and providing wearable smart devices and connectivity services targeted at children and families in various countries including Germany, Sweden, Norway, the UK, Finland, Denmark, Spain, the US, and France.
Insider Ownership:21.3%
Xplora Technologies is positioned for growth with forecasted annual earnings increases of 74.43% and revenue growth of 11.6%, surpassing the Norwegian market average. Despite a net loss for the nine months ending September 2025, the company reported significant subscription growth, reaching 476k by December 2025. Trading at a substantial discount to its estimated fair value, Xplora's high insider ownership aligns with expectations of profitability within three years, though recent insider activity shows significant selling.
Rusta
Simply Wall St Growth Rating:★★★★★☆
Overview:Rusta AB (publ) operates as a retailer offering home decoration, consumables, seasonal products, leisure items, and DIY categories across Sweden, Norway, Finland, and Germany with a market cap of SEK12.59 billion.
Operations:The company's revenue is segmented into SEK7.16 billion from Sweden, SEK2.59 billion from Norway, and SEK2.41 billion from other markets.
Insider Ownership:13.5%
Rusta demonstrates growth potential with forecasted annual earnings increases of 21%, outpacing the Swedish market. Recent insider activity shows more buying than selling, although not in large volumes. The company trades at a significant discount to its estimated fair value and reports improved Q2 2025 results, with sales reaching SEK 2.95 billion and net income at SEK 106 million. Upcoming leadership change may influence strategic direction as Cathrine Wigzell takes over as CEO in June 2026.
-
Click here to discover the nuances of Rusta with our detailed analytical future growth report.
-
Our valuation report here indicates Rusta may be overvalued.
Turning Ideas Into Actions
-
Investigate our full lineup of 227 Fast Growing European Companies With High Insider Ownership right here.
-
Interested In Other Possibilities? AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ENXTPA:MEDCL OB:XPLRA and OM:RUSTA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
